

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

1 **Prevalence of Neutralizing Antibodies against Adenoviruses types -C5, -D26 and -**  
2 **B35 used in vaccination platforms, in Healthy and HIV-Infected Adults and Children**  
3 **from Burkina Faso and Chad**

4 Aline Raissa Ouoba<sup>1</sup>, Océane Paris<sup>1</sup>, Chatté Adawaye, Guy Takoudjou Dzomo,  
5 Abderrazzack Adoum Fouda, Dramane Kania, Amidou Diarra, Zenaba Abdramane Kallo,  
6 Isidore Tiandiogo Traore, Sodiomon Bienvenu Sirima, Edouard Tuailon, Philippe Van de  
7 Perre, Eric J. Kremer<sup>2</sup>, Franck Jean Daniel Mennechet<sup>3</sup>

8 @ Correspondence to: [franck.mennechet@umontpellier.fr](mailto:franck.mennechet@umontpellier.fr)

9 Author affiliations: University of Montpellier, INSERM, EFS, Antilles University,  
10 Montpellier, France (A.R. Ouoba, F.J. D. Mennechet, E. Tuailon, P.Van de Perre);  
11 University of Montpellier, CNRS, IGMM (O. Paris, E.J. Kremer, F.J.D. Mennechet);  
12 Faculty of Human Health Sciences, N'Djamena, Chad (C. Adawaye); University Hospital  
13 Complex "Le Bon Samaritain", N'Djamena, Chad (G.T. Dzomo); Toumaï University,  
14 N'Djamena, Chad (A.A. Fouda, Z.A. Kallo); Sectoral AIDS Control Program, N'Djamena,  
15 Chad (A.A. Fouda). Centre MURAZ, Bobo-Dioulasso, Burkina Faso (A.R. Ouoba, D.  
16 Kania, I.T. Traore); Institute of Health Sciences, University of Nazi Boni, Bobo-Dioulasso,  
17 Burkina Faso (I.T. Traore), National Institute of Public Health, Ouagadougou, Burkina Faso  
18 (D. Kania). National Malaria Research and Training Center, Ouagadougou, Burkina Faso  
19 (S.B. Sirima, A. Diarra); Health Action Research Group, Ouagadougou, Burkina Faso (S.B.  
20 Sirima, A. Diarra).

21 <sup>1</sup>These authors contributed equally to this study

22 <sup>2</sup>Co-senior authors

23 **Article summary line:** HAdVs Seroprevalence in Burkina Faso and Chad

24 **Keywords:** Vaccination, Adenovirus, HAdV-D26, HAdV-B35, Seroprevalence, Dendritic  
25 Cells, Virus-derived vaccines, Burkina Faso, Chad, Alternative HAdV

26 **Abstract**

27 Vaccines derived from human adenoviruses (HAdV) are currently being used and trialed  
28 against numerous infectious agents. However, pre-existing humoral immunity can impair  
29 vaccines efficacy and safety. Strategies to circumvent this immunity often involve the use  
30 of vectors with lower seroprevalence. We evaluated HAdV-C5, HAdV-D26 and HAdV-B35  
31 seroprevalence from healthy and HIV-infected populations from Burkina Faso and Chad.  
32 Seroprevalence for HAdV-C5 was high and comparable between countries (54%-66%), and  
33 the highest in the HIV-infected groups from sub-Saharan regions (~90%). However,  
34 compared to France (4%), seroprevalence for HAdV-D26 was significantly higher in sub-  
35 Saharan groups (~47%). By contrast, HAdV-B35 seroprevalence was low for all groups  
36 tested. We also found that HAdV-D26 complexed with immunoglobulins induced strong  
37 activation of dendritic cells in vitro. Our study fills gaps in the epidemiological data needed  
38 to optimize HAdV-derived vaccines in sub-Saharan regions, and highlights the necessity to  
39 better adjust vaccination strategies in Africa.

## 40 **Introduction**

41 Vaccines save millions of lives every year and limit major financial and public health  
42 system losses (1). As of April 4<sup>th</sup> 2022, ~17% (25/153) of COVID-19 vaccines are viral  
43 vector-derived (2). Among them, five are human adenovirus (HAdV) based, including  
44 Convidecia (CanSino Biologics), Sputnik V (Gamaleya Research Institute), and the Johnson  
45 & Johnson/Janssen (3). The most widely distributed COVID-19 vaccine is Vaszevria  
46 (ChAdOx1-S), a chimpanzee adenovirus-derived vaccine developed by Oxford  
47 University/AstraZeneca. HAdVs were among the first vectors developed for gene  
48 transfer/vaccines. Among the ~100 ~HAdV types, HAdV species C type 5 (HAdV-C5) is  
49 the best characterized and is the most widely used (4).

50 A drawback in the use of HAdV-derived vaccines is pre-existing immunity that impairs  
51 vaccine efficacy and potential immunotoxicity (5,6). Current data suggest that both innate  
52 and adaptive immune responses impact the duration of transgene expression from HAdVs  
53 (7). Natural infection or the administration of AdV vectors in pre-immune subject results in  
54 an activation of innate immune responses associated with the production of pro-  
55 inflammatory cytokines/chemokines, following by an adaptive immunity, including T and  
56 B cell responses. Although HAdV-induced T cells are responsible for the lysis of cells  
57 expressing viral and transgenic products (8), anti-HAdV Abs favor capsid uptake by  
58 antigen-presenting cells through Fc receptors (9,10). HAdV-C5-based vaccines have  
59 therefore shown an inverse correlation between efficacy/safety and pre-existing humoral  
60 immunity. A better understanding of the interaction between innate and pre-existing  
61 immunity, vaccines, is a major objective in the development of Ad-derived vaccines.

62 Several strategies have been deployed to bypass humoral immunity, including genetic and  
63 chemical modifications of the capsid, generation of chimeric vectors, and the use of AdV

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

64 with low seroprevalence (6). Alternative candidates to HAdV-C5 are numerous, but only  
65 HAdV-D26, -B35 and -E4 are currently in clinical trials/use (11). HAdV-D26-based  
66 vaccines have been extensively tested in multiple clinical programs (12,13). Depending on  
67 the trial, HAdV-D26-derived vaccines are generally used in prime-boost heterologous  
68 strategies with the modified vaccinia Ankara or other HAdV types of such as HAdV-B35  
69 or HAdV-C5. For COVID-19 vaccine, Ad26.COV2.S is a single dose (13), and Sputnik is  
70 a heterologous vaccine using HAdV-D26 with -C5 in a prime-boost regimen (14). HAdV-  
71 B35 on other hand is not among candidates of COVID-19 vaccines, but has long been part  
72 of the vaccination landscape for many infectious diseases, in particularly HIV (15), Ebola  
73 virus (16), malaria (17) and tuberculosis (18), which are particularly devastating in sub-  
74 Saharan Africa.

75 While HAdV-C5 seroprevalence is well documented, data on HAdV-D26 and HAdV-B35  
76 are less extensive (11). For HAdV-D26, accumulating evidence shows that seroprevalence  
77 in Europe and North America rarely exceeds 10% (11,19). The few studies conducted on  
78 the seroprevalence of HAdV-D26 in Africa have shown seroprevalence between 10 and  
79 90%, with low or intermediate NAb titers compared to HAdV-C5 (20–22). For HAdV-B35,  
80 seroprevalence is generally low worldwide, with rates slightly higher in some sub-Saharan  
81 regions (11,23,24). However, global mapping of the seroprevalence of HAdV-D26 and  
82 HAdV-B35 remains incomplete. These gaps make HAdV-derived COVID-19 vaccines less  
83 predictable in populations that are globally more affected by infectious diseases.

84 In this study, we quantified HAdV-C5, -D26 and -B35 seroprevalence in individuals from  
85 Burkina Faso and Chad. In contrast to Europe & North America, our study indicates that  
86 HAdV-D26 seroprevalence is high, particularly in people living with HIV. By contrast,

87 HAdV-B35 seroprevalence is low in all the cohorts tested. Moreover, immunoglobulin-  
88 complexed HAdV-D26s stimulate the activation of human phagocytes.

## 89 **Methods**

### 90 **Sample location and management**

91 This cross-sectional study was conducted on 424 plasma samples from Burkina Faso (241),  
92 Chad (93) & France (50) (**Table 01**). Samples were collected from adults or children, HIV-  
93 infected, or HIV-uninfected donors. Samples from HIV-uninfected subjects in Burkina Faso  
94 were collected in 2012 at the National Malaria Research and Training Center (CNRFP) and  
95 the Centre MURAZ in 2017. Collection and use of plasma samples for this study was  
96 approved by institutional review boards of the CNRFP (AEP-04/07/20 1O/CIB-CNRFP)  
97 and Institutional Ethic Committee of the Centre MURAZ (N°2017-361/MS/SG/CM/DG).  
98 For Chad, HIV-uninfected samples were collected at the "Bon Samaritain" hospital (from  
99 December 2018 to November 2019). In France, samples were provided by the French Blood  
100 service (EFS, France) and the study was approved by the Occitanie & Midi-Pyrenees EFS  
101 scientific board (EFS-OCPM: N°21PLER2019-0002). Samples from HIV-infected subjects  
102 from Burkina Faso were randomly selected from the ANRS 12174 Promise-PEP trial sample  
103 collection (20), in accordance with the sub-study request established and approved by  
104 Institutional Ethic Committee of the country. For Chad, samples from HIV-infected subjects  
105 were collected in 2019 at the Sectorial AIDS Control Program Center (PSLS) in the city of  
106 N'Djamena. All samples were supported by a written and signed informed consent.

### 107 **Adenoviruses, cells, and culture conditions**

108 For neutralization assays, 911 cells were cultured as described previously (25). For *ex vivo*  
109 MoDC stimulation assay, blood was obtained from healthy adult donors via the EFS,  
110 Montpellier, France and processed as previously described (26). GFP-expressing HAdVs

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

111 were amplified in (HEK) 293 or 911 cells and purified, and quantified as previously  
112 described (27) Vector purity typically reached >99%. HAdV-D26-GFP was provided by  
113 Dr. Eric Weaver (University of Nebraska-Lincoln, USA) and HAdV-B35-GFP by Andre  
114 Lieber (University of Washington, Seattle, USA).

115 **Adenovirus neutralization assays**

116 For neutralizing antibody (NAb) titration tests, 911 cells were seeded at  $10^5$  cells/well in  
117 24-well plates and left to attach for 1 h. Plasma were diluted from 1:40 to 1:2160 and pre-  
118 incubated during 30 mins at 20°C with GFP-expressing-HAdV at 15, 100 or 500 pp/cell for  
119 HAdV-C5, B35 and D26, respectively. As the seroprevalence of HAdV-B35 is typically  
120 low, a pre-screening at 1:10, 1:100 and 1:1000 sample dilutions was performed to select  
121 samples of interest. Two-fold dilutions of the HAdV of interest were systematically  
122 included in duplicate to control the infectivity capacity of the vectors. HAdV standards,  
123 controls, and samples were cultured with cells for 20 h at 37°C and 5% of CO<sub>2</sub>. The next  
124 day, the cells were collected and assayed for GFP expression by flow cytometry  
125 (FACScalibur®- BD Bioscience or NovoCyte ACEA®- Agilent). The NAb titers was  
126 quantified by identifying the sample dilutions that generate 50% of GFP+ cells. Samples  
127 were considered positive when NAb titer  $\geq$  100. Data analyses were performed using the  
128 FlowJo software (BD Bioscience, France).

129 **Immune complexes formation and DC stimulation**

130 Monocyte-derived DCs (MoDCs) were challenged as previously described (9) using vectors  
131  $\pm$  plasma, plasma, LPS (500 ng/ml), or IVIg® (Baxter SAS, Guyancourt, France). Plasma  
132 were pre-incubated individually with either HAdV-C5, D26 or B35 (at 1000 pp/cell) prior  
133 to *in vitro* MoDC challenge. When appropriate, plasma were classified into four groups  
134 according to their serological profile: (C5+, D26-), (C5+, D26-), (C5-, D26-) and (C5+,

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

135 D26+) and pre-incubated with HAdV-C5 or D26 before the MoDC challenge. Plasma were  
136 tested repeatedly on MoDCs generated from different blood donors (n=3 to 6). Supernatants  
137 were collected after 14 h of culture and tested for TNF secretion by ELISA according to the  
138 manufacturer instructions (OptEIA human TNF ELISA Kit, BD Biosciences).

139 **Statistical analyses**

140 All data were analysed using GraphPad Prism 5 software. Statistical analyses were  
141 determined using non-parametric Mann Whitney U test when two groups are compared and  
142 Kruskal Wallis ANOVA analyses for multiples inter-group comparisons. The non-  
143 parametric Spearman test correlation test was used to evaluate the association between NAb  
144 titers and TNF levels ( $r_s$  (rho): Spearman rank correlation). Correlation tests were performed  
145 with the online statistical tools for high-throughput data analysis (STHDA) (28).

146 **Results**

147 **NAb titers for HAdV-C5, HAdV-D26, and HAdV-B35**

148 We first evaluated the prevalence NAb in HIV-uninfected subjects from Burkina Faso,  
149 Chad, and France (**Figure 1 & 2B**). Consistent with previous reports, the majority ( $60 \pm$   
150  $5\%$ ) of adults in all regions have HAdV-C5 NAb, with median titers (IQR) of 643, 521 and  
151 591 for Burkina Faso, Chad and France, respectively. For HAdV-D26, about 48% of  
152 individuals from the African countries have NAb, whereas found no sample with NAb titers  
153  $\geq 1000$  in the French group. The median NAb titers were 407, 333 and 30 for Burkina Faso,  
154 Chad and France, respectively. By contrast, no sample showed significant titers for HAdV-  
155 B35 NAb.

156 Individual NAb titers were stratified into three categories:  $\leq 99$  (negative or low), 100-999  
157 (medium) and  $\geq 1000$  (high) (**Figures 2A & 2B**). For HAdV-C5, 55%-66% of the African  
158 subjects had titers  $\geq 100$  and 22%-30% had Titers  $\geq 1000$ . In France,  $\sim 66\%$  of the cohort  
159 had NAb titers  $\geq 100$  and  $\sim 18\%$  were  $\geq 1000$ . For HAdV-D26,  $\sim 48\%$  of the individuals had  
160 NAb titers  $\geq 100$  in Burkina Faso and Chad, compared to only 4% in France. Additionally,  
161  $\sim 13\%$  of the samples had high HAdV-D26 NAb titers in the sub-Saharan groups.  
162 Seroprevalence was as follows (NAb threshold  $\geq 100$ ): HAdV-C5 - 55% (143/261) and  
163 HAdV-D26 - 48% (126/261) in Burkina Faso; HAdV-C5 - 63% (29/46) and HAdV-D26 -  
164 48% (22/46) in Chad, compared to HAdV-C5 - 66% (33/50) and HAdV-D26 4% (2/50) in  
165 the French cohort (**Figure 2B**).

166 We found no samples with HAdV-B35 NAb titer greater than 100, and a seroprevalence  $<$   
167 6% for all groups tested (**data not shown**). **Figure 2C** shows the distribution of NAb titers  
168 among positive samples from Burkina Faso. NAb titres were stratified into three categories:  
169 low or moderate (100-499), medium (500-999) and high ( $\geq 1000$ ). The majority of samples



170 exhibited medium (11%) or high (54%) NAb titers for HAdV-C5 (65% total), while most  
171 of the cohort (58%) had low or moderate level of HAdV-D26 NAb. Nevertheless, 15% of  
172 the positive samples had medium NAb titers to HAdV-D26, and 27% had NAb titers  $\geq$  1000  
173 (42% total).

#### 174 **Correlation between NAb titers, sex, age, and HIV status in Burkina Faso**

175 To better understand the natural history of HAdV infection among sub-Saharan populations,  
176 we explored possible relationships between HAdV seroprevalence and gender. We found no  
177 associations between single or dual-positive groups for HAdV-C5 and HAdV-D26 (**Figure**  
178 **S1A**), and no differences in medians titer distribution according to sex (**Figure S1B & C**).  
179 Assuming that HAdV type-specific NAb titers will wane over time, the comparison of  
180 seroprevalence between different age groups also does not indicate an age-dependent  
181 susceptibility to infections (**Figure S2A**) or the average NAb titers (**Figure S2B**). However,  
182 seroprevalence for both HAdVs appears to increase overall with age, peaking in young  
183 adults and maintained throughout life.

#### 184 **Immune-complexed (IC) HAdV-D26 activates MoDCs**

185 We previously showed that IC-HAdV-C5 induces AIM2-associated pyroptosis in primary  
186 cultures of human phagocytes (29,30). To evaluate the impact of IC-HAdV-D26, we  
187 challenged MoDCs with plasma containing NAb, preincubated with the respective HAdVs  
188 and then quantified TNF secretion. We divided plasma into groups according to their  
189 serological profile: single positive (HAdV-C5+/HAdV-D26-) and (HAdV-C5-/HAdV-  
190 D26+), dual positive (HAdV-C5+/HAdV-D26+) and dual negative (HAdV-C5-/HAdV-D26-  
191 ). We also ensured that groups had similar sampling and comparable mean NAb titers. The  
192 HAdV-C5+/HAdV-D26- samples induced significantly higher production of TNF with  
193 HAdV-C5 compared to HAdV-D26, whereas the opposite was observed with the HAdV-C5-

194 /HAdV-D26+ plasma group (**Figure 3A**). The dual-positive group (HAdV-C5+/HAdV-  
195 D26+) induced significantly higher TNF production for both vectors in comparison to the  
196 dual-negative group (HAdV-C5-/HAdV-D26-). Additionally, TNF secretion for a given  
197 virus were comparable (regardless of the serological profile of the other virus).

198 Monotonic regression analyses to examine the correlation between HAdVs NAb titers and  
199 the level of TNF secretion suggested modest correlation ( $r_s$ : 0.62 and 0.58) between the IC-  
200 HAdV-C5 and -D26 (**Figure 3B**). We then quantified the average production of TNF by  
201 MoDCs, pre-incubated with each plasma individually, and independently of their  
202 serological profile. This approach provides an overall estimate of the innate immune  
203 response to the HAdVs in a given population. The average TNF secretion level was  
204 significantly higher with HAdV-C5, followed by HAdV-D26 and HAdV-B35, respectively  
205 (**Figure 3C**). Additionally, TNF secretion was significantly higher for HAdV-D26  
206 compared with HAdV-B35. By contrast, MoDC activation with plasma from France ( $n=15$ )  
207 was modest with HAdV-D26 and HAdV-B35 compared to HAdV-C5 (**data not shown**).

### 208 **HAdV seroprevalence and MoDC TNF secretion according to HIV status**

209 HIV is a major burden in sub-Saharan Africa and HAdV infections are common in people  
210 with immunodeficiency, especially for HAdV-Ds, frequently isolated from  
211 immunocompromised individuals. To determine whether HAdV seroprevalence is linked to  
212 HIV status, we first evaluated the mean NAb titers in HIV-infected versus uninfected  
213 controls (**Figure 4A**). For samples collected in Burkina Faso, mean NAb titers for HAdV-  
214 C5 only were significantly higher in the HIV-infected group. However, in Chad, this  
215 increase was observed for the three HAdV tested. Of note, seroprevalence reached ~90%  
216 for HAdV-C5 and HAdV-D26 and 24% for HAdV-B35, compared to 63%, 48%, and 0% for  
217 uninfected controls (**Figure 2B & 4A**). In addition, HIV-infected subjects tended to have a

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

218 higher proportion of high NAb titers for both HAdV-C5 52% (25/46) and HAdV-D26 39%  
219 (18/46) (**data not shown**) compared to the HIV-uninfected groups (**Figure 2A**).

220 Using IC-HAdVs (plasma + HAdVs) we then analysed the correlation between NAb titers  
221 and TNF production by MoDC for samples collected from people HIV-infected and  
222 uninfected individuals from Chad. In concordance with our previous observation (**Figure**  
223 **3B**), we found a positive but moderate correlation (**Figure 4C**) that was higher when  
224 plasmas were pre-incubated with HAdV-C5 compared to HAdV-D26. Finally, we  
225 compared the ability of plasmas to induce TNF secretion from MoDCs according to their  
226 HIV status. We found no difference in either of the HAdVs tested for stimulation between  
227 the HIV-infected and uninfected groups (**Figure 4D**). However, we observed by comparison  
228 that plasma samples incubated with HAdV-C5 or HAdV-D26 induced greater TNF levels  
229 compared to HAdV-B35, regardless of the HIV status. No significant differences were found  
230 between HAdV-C5 and HAdV-D26. For HAdV-B35, only the HIV-uninfected group  
231 reached a significant variation compared with HAdV-D26. Finally, we observed that TNF  
232 production was ~3-fold higher in samples from Chad compared to Burkina Faso, regardless  
233 of HIV serologic profile and for all three HAdVs tested (**Figure 3C & 4D**).

234 **Discussion**

235 All vaccines, and in particular those derived from HAdVs, must be vetted judiciously (31).  
236 We are just beginning to understand the biological mechanisms that govern the interactions  
237 between pre-existing immunity, alarmins, coagulation factors and the effectiveness of  
238 HAdV vectors (32). In addition to affecting the efficacy of the vaccine, the adverse events  
239 of the STEP/Phambili trials from the HIV Vaccine Trials Network (HVTN) illustrate the  
240 need to take precautions (33). In this study, we found high HAdV-C5 seroprevalences as  
241 previously reported in other sub-Saharan regions (11,20–22). However, for HAdV-D26,  
242 limited information was available. Our results on the French group confirmed a low HAdV-  
243 D26 seroprevalence in Europe (21). Investigations performed on rural populations from  
244 other sub-Saharan African countries showed relative high prevalence and genetic diversity  
245 among the species D of HAdV (HAdV-Ds) (34). This study also suggested that the fecal-  
246 oral transmission, hygiene measures, nutrition and local infectious burden play a role in  
247 HAdV-Ds spread.

248 The majority of studies on HAdV-D26 or -B35 seroprevalence were conducted by  
249 pharmaceutical companies to monitor the clinical applicability and of HAdV in a context of  
250 vaccine development. We found a higher HAd-C5 and -D26 seroprevalence and mean NAb  
251 titers in sub-Saharan cohorts compared to France (20–22). One study, however, found very  
252 high NAb seroprevalence and titers for HAdV-D26 in cohorts from Cameroun, similar to or  
253 higher than HAdV-C5 (19). These data also highlight the discrepancy between studies  
254 regarding the level of HAdV-D26 seroprevalence in African cohorts. Taken together, these  
255 studies showed that HAdV-D26 seroprevalence in sub-Saharan zone ranges from 45-88%.  
256 However, the studies also generally showed that the proportion of people with a high NAb  
257 titer ( $\geq 1000$ ) for HAdV-D26 was low (3.4% overall with a maximum of 6.3% in South

258 Africa) (21,22,35). Within our groups, we found a relatively high proportion of individuals  
259 with HAdV-D26 NAb titers above those anticipated affecting the performance of a HAdV-  
260 based vaccines (**Figure 2C**). The proportion of samples having NAb titers  $\geq 1000$  was the  
261 highest in the HIV-infected group from Chad, reaching  $\sim 40\%$ .

262 HAdV-B35 seroprevalence was low for all groups tested (**Figures 1A & 2A**). Consistent  
263 with other studies, seroprevalence for all HAdVs was independent of the donor's gender  
264 (36). For the pediatric population, outcomes are sometimes contradictory, indicating either  
265 lower seroprevalence compared to adults (36), or that infections/seroconversion occurred  
266 relatively early in life, then waned with age (21,37). In our study, we found that NAb  
267 serprevalence increased with age, but the mean NAb titer did not vary significantly (**Figures**  
268 **S2A & S2B**).

269 HIV is a major burden in sub-Saharan Africa. In addition, HAdV infections are common in  
270 people with immunodeficiency (38) and can cause significant morbidity, especially for  
271 HAdV-Ds (39). Asymptomatic HAdV infections are also frequent in HIV-infected patients  
272 who are not on antiretroviral therapy. However, most studies conducted on HAdV-C5 and  
273 HIV status showed a comparable seroprevalence between HIV-infected and non-infected  
274 individuals, which remains constant over the course of the progression to AIDS (40). For  
275 HAdV-D26 or HAdV-B35, the correlation between HIV status and seroprevalence was  
276 rarely described. Older studies showed that HAdV-B35 was preferentially isolated from  
277 immunocompromised patients with AIDS (41), but did not indicate significant variations in  
278 subjects from the United States or Africa, for both HAdV-D26 and HAdV-B35 (22,42). In  
279 China, however, HAdV-D26 seroprevalence is higher in the population at high risk for HIV  
280 infection than in the low risk cohort (43). In our study, HAdV-C5 seroprevalence was  
281 significantly higher for the HIV-infected groups compared to the general population in

282 Burkina Faso and for all three HAdVs tested in Chad (**Figure 4A**). Despite numerous reports  
283 reflecting the importance of HAdV in patients with AIDS, the opportunistic role of this  
284 pathogen is poorly documented and, considering these data, may be underestimated in sub-  
285 Saharan Africa.

286 To better understand the consequences of HAdV NAb, we used an *ex vivo* model based on  
287 MoDC activation (9). With this system, we show consistent TNF secretion according to the  
288 HAdV serological profiles (**Figure 3A**). However, some samples occasionally induced  
289 MoDC activation even though they were HAdV-NAb negative/low. This observation was  
290 confirmed by the moderate correlation observed between the NAb titers of the samples and  
291 the level of MoDC activation (**Figure 3B**). We hypothesize that non-NAbs can form  
292 complexes and activate MoDC. It has been established that HAdV humoral response is  
293 directed against multiple capsid components (44). The dogma in the field suggests that  
294 NAb induced by HAdV natural infection lead to poor cross-reactivity, but this has not been  
295 systematically analysed. In addition, studies have shown a probable cross-protection  
296 between HAdVs from the same species (45,46).

297 We previously found that the amount of TNF secreted reflects the activation of the host  
298 immune response and could therefore be indicative of vaccine efficacy. The Inflammatory  
299 response induced by HAdV-D26 and HAdV-B35 are generally lower in comparison to  
300 HAdV-C5, which correlates with the seroprevalence profiles observed for these populations  
301 (**Figure 3C**). However, the differences between HAdVs were less evident for samples  
302 collected in Chad (**Figure 4D**). Our analyses showed similar TNF production for all three  
303 HAdVs in HIV-infected participants. The amount of TNF secreted by MoDC was also  
304 higher in subjects from Chad compared to Burkina Faso in general. We presume the  
305 possibility of numerous cross-reactions, or the involvement of other factors linked to

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

306 environment and exposure to infectious agents, but also to genetic variations, which may  
307 influence the immune response to HAdVs-derived vaccines (47). In addition, several  
308 extracellular proteins in plasma interact with HAdV and can increase the uptake by and  
309 activation of DC (48).

310 Will HAdV-D26 or -B35-based vaccines prime individuals for infection by HIV? (49).  
311 According to the vaccine manufacturers, there is no clinical evidence to date that pre-  
312 existing immunity, whether natural or vector-induced, influences or blunts the efficacy of  
313 HAdV-D26 or B35-derived vaccines (12). These studies suggested that the major difference  
314 with HAdV-C5 could be explained by biological variables such as receptor usage (12).  
315 However, we demonstrate that individuals with high HAdV-D26 NAb titers are common in  
316 some sub-Saharan areas, with rates comparable to those of HAdV-C5. We found that plasma  
317 from people HIV-infected + HAdV-C5 or HAdV-D26 can efficiently activate MoDC. Thus,  
318 we share the concerns about the use of HAdV-based vaccines in sub-Saharan zones with  
319 high HIV endemic populations (49,50). The risk/benefit assessment of HAdV-derived  
320 vaccines must address HAdVs seroprevalence. We also recommend surveillance of de novo  
321 HIV infections in high HIV-prevalent populations. In addition, our study underscores the  
322 need to pre-evaluate the efficacy and safety of vaccines in sub-Saharan populations. These  
323 recommendations are all the more important as we may be living through a crucial and  
324 unique turning point in the history of vaccination, which could influence future strategies  
325 to reduce vaccine hesitancy worldwide.

326 **Acknowledgments**

327 We thank Mehdi Taleb, Sofia Salazar Arenas, Chloé Houques, Lumen Ishimwe, Aboudou  
328 Djobo, Lucas August, Marina Lavigne, Hiep Tran, Coraline Cheneau, TT Phuong Tran,  
329 Karsten Eichholz, Karine Bollore et Jean Pierre Molès for reagents and technical help. We  
330 thank Thierry Gostan and Myriam Boyer for their help on statistical analyses and flow  
331 cytometry, respectively. EJK is an INSERM fellow. We are grateful to Eric A. Weaver and  
332 Andre Lieber for the gift of HAdV-D26 and HAdV-B35, respectively.

333 **Funding statement**

334 This study was supported by the University of Montpellier (EJK), the Pierre Fabre  
335 Foundation (FJDM), the National Institute of Health and Medical Research (INSERM)  
336 (PVDP), The University Hospital Complex of Montpellier (ET), the University Hospital  
337 Complex “Le Bon Samaritain” (GTZ), the Centre MURAZ (ARO), and The French Ministry  
338 of Higher Education (OP).

339 **Declaration of interest statement**

340 The authors declare that they have no known competing financial interests or personal  
341 relationships that could have appeared to influence the work reported in this paper.

342 **Biographical Sketch of the first author**

343 Dr Ouoba is a pharmacist and obtained a PhD in immunology/virology from the University  
344 of Montpellier, France. She works on diseases with epidemic potential at the Muraz research  
345 centre in Bobo Doulasso, Burkina Faso. Her main research interests are the detection and  
346 prevention of viral infections in sub-Saharan areas.



347 **References**

- 348 1. Ehreth J. The global value of vaccination. *Vaccine*. 2003 Jan 30;21(7–8):596–600.
- 349 2. WHO. Draft landscape and tracker of COVID-19 candidate vaccines [Internet]. 2021  
350 [cited 2021 May 12]. Available from: [https://www.who.int/publications/m/item/draft-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)  
351 [landscape-of-covid-19-candidate-vaccines](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)
- 352 3. Krammer F. SARS-CoV-2 vaccines in development. *Nature*. 2020 Oct  
353 1;586(7830):516–27.
- 354 4. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical  
355 trials worldwide to 2017: An update. *J Gene Med*. 2018 May;20(5):e3015.
- 356 5. Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune Responses to Viral Gene  
357 Therapy Vectors. *Mol Ther*. 2020 Mar 4;28(3):709–22.
- 358 6. Jönsson F, Kreppel F. Barriers to systemic application of virus-based vectors in gene  
359 therapy: lessons from adenovirus type 5. *Virus Genes*. 2017 Oct;53(5):692–9.
- 360 7. Gregory SM, Nazir SA, Metcalf JP. Implications of the innate immune response to  
361 adenovirus and adenoviral vectors. *Future Virol*. 2011 Mar;6(3):357–74.
- 362 8. Tang J, Olive M, Pulmanusahakul R, Schnell M, Flomenberg N, Eisenlohr L, et al.  
363 Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. *Virology*.  
364 2006 Jul 5;350(2):312–22.
- 365 9. Eichholz K, Bru T, Tran TTP, Fernandes P, Welles H, Mennechet FJD, et al.  
366 Immune-Complexed Adenovirus Induce AIM2-Mediated Pyroptosis in Human  
367 Dendritic Cells. *PLoS Pathog*. 2016 Sep;12(9):e1005871.

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

- 368 10. Zaiss AK, Vilaysane A, Cotter MJ, Clark SA, Meijndert HC, Colarusso P, et al.  
369 Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate  
370 immune response. *J Immunol*. 2009 Jun 1;182(11):7058–68.
- 371 11. Mennechet FJD, Paris O, Ouoba AR, Salazar Arenas S, Sirima SB, Takoudjou  
372 Dzomo GR, et al. A review of 65 years of human adenovirus seroprevalence. *Expert*  
373 *Rev Vaccines*. 2019 Jun;18(6):597–613.
- 374 12. Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, et al. Vaccines  
375 based on replication incompetent Ad26 viral vectors: Standardized template with key  
376 considerations for a risk/benefit assessment. *Vaccine* [Internet]. 2020 Oct 3;  
377 Available from:  
378 <https://www.sciencedirect.com/science/article/pii/S0264410X20311609>
- 379 13. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al.  
380 Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. *N Engl J*  
381 *Med*. 2021 Jan 13;
- 382 14. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV,  
383 Dzhharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-  
384 based heterologous prime-boost COVID-19 vaccine in two formulations: two open,  
385 non-randomised phase 1/2 studies from Russia. *Lancet*. 2020 Sep  
386 26;396(10255):887–97.
- 387 15. Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert PB, Kochar N, et al. Safety and  
388 Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine

- 389 in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. *J AIDS Clin*  
390 *Res.* 2015 May;6(5).
- 391 16. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, et al.  
392 Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass  
393 immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. *J*  
394 *Virol.* 2011/02/16 ed. 2011 May;85(9):4222–33.
- 395 17. Ockenhouse CF, Regules J, Tosh D, Cowden J, Kathcart A, Cummings J, et al.  
396 Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against  
397 Sporozoite Challenge in Healthy Malaria-Naïve Adults. *PLoS One.*  
398 2015;10(7):e0131571.
- 399 18. Churchyard GJ, Snowden MA, Hokey D, Dheenadhayalan V, McClain JB, Douoguih  
400 M, et al. The safety and immunogenicity of an adenovirus type 35-vectored TB  
401 vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350  
402 cells/mm<sup>3</sup>. *Vaccine.* 2015 Apr 8;33(15):1890–6.
- 403 19. Chen H, Xiang ZQ, Li Y, Kurupati RK, Jia B, Bian A, et al. Adenovirus-based  
404 vaccines: comparison of vectors from three species of adenoviridae. *J Virol.*  
405 2010/08/04 ed. 2010 Oct;84(20):10522–32.
- 406 20. Abbink P, Lemckert AAC, Ewald BA, Lynch DM, Denholtz M, Smits S, et al.  
407 Comparative seroprevalence and immunogenicity of six rare serotype recombinant  
408 adenovirus vaccine vectors from subgroups B and D. *J Virol.* 2007 May;81(9):4654–  
409 63.

- 410 21. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, et al.  
411 International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6,  
412 type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and  
413 implications for potential HIV vaccine trials. *Vaccine*. 2010 Jan 22;28(4):950–7.
- 414 22. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al.  
415 International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric  
416 and adult populations. *Vaccine*. 2011 Jul 18;29(32):5203–9.
- 417 23. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, et  
418 al. Replication-deficient human adenovirus type 35 vectors for gene transfer and  
419 vaccination: efficient human cell infection and bypass of preexisting adenovirus  
420 immunity. *J Virol*. 2003 Aug;77(15):8263–71.
- 421 24. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, et al. Prevalence of  
422 neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of  
423 The Gambia, South Africa, and the United States. *Clin Diagn Lab Immunol*. 2004  
424 Mar;11(2):351–7.
- 425 25. Danthinne X, Werth E. New tools for the generation of E1- and/or E3-substituted  
426 adenoviral vectors. *Gene Ther*. 2000 Jan;7(1):80–7.
- 427 26. Perreau M, Kremer EJ. Frequency, proliferation, and activation of human memory T  
428 cells induced by a nonhuman adenovirus. *J Virol*. 2005 Dec;79(23):14595–605.
- 429 27. Kremer EJ, Boutin S, Chillon M, Danos O. Canine adenovirus vectors: an alternative  
430 for adenovirus-mediated gene transfer. *J Virol*. 2000 Jan;74(1):505–12.

- 431 28. Alboukadel Kassambara. STHDA Statistical tools for high-throughput data analysis  
432 [Internet]. Available from: <http://www.sthda.com/english/>
- 433 29. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5  
434 immune complexes creates an improved environment for replication of HIV in T  
435 cells. *J Exp Med*. 2008 Nov 24;205(12):2717–25.
- 436 30. Eichholz K, Bru T, Tran TTP, Fernandes P, Welles H, Mennechet FJD, et al.  
437 Immune-Complexed Adenovirus Induce AIM2-Mediated Pyroptosis in Human  
438 Dendritic Cells. *PLoS Pathog*. 2016 Sep 16;12(9):e1005871–e1005871.
- 439 31. Kremer EJ. Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines. *Mol Ther*.  
440 2020 Nov 4;28(11):2303–4.
- 441 32. Chéneau C, Eichholz K, Tran TH, Tran TTP, Paris O, Henriquet C, et al. Lactoferrin  
442 Retargets Human Adenoviruses to TLR4 to Induce an Abortive NLRP3-Associated  
443 Pyroptotic Response in Human Phagocytes. *Front Immunol*. 2021;12:685218.
- 444 33. Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP. Immunology.  
445 Immune activation with HIV vaccines. *Science*. 2014 Apr 4;344(6179):49–51.
- 446 34. Pauly M, Hoppe E, Mugisha L, Petrzalkova K, Akoua-Koffi C, Couacy-Hymann E,  
447 et al. High prevalence and diversity of species D adenoviruses (HAdV-D) in human  
448 populations of four Sub-Saharan countries. *Viol J*. 2014 Feb 11;11:25–25.
- 449 35. Ersching J, Hernandez MIM, Cezarotto FS, Ferreira JDS, Martins AB, Switzer WM,  
450 et al. Neutralizing antibodies to human and simian adenoviruses in humans and New-  
451 World monkeys. *Virology*. 2010 Nov 10;407(1):1–6.

- 452 36. Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AAC, et al.  
453 Age dependence of adenovirus-specific neutralizing antibody titers in individuals  
454 from sub-Saharan Africa. *J Clin Microbiol.* 2006 Oct;44(10):3781–3.
- 455 37. Ghasemi Y, Makvandi M, Samarbazadeh AR, Nejati A, Najafifard S, Neisi N, et al.  
456 Serotype determination of adenoviruses in children with respiratory infection. *Indian*  
457 *J Pediatr.* 2014 Jul;81(7):639–43.
- 458 38. Al-Herz W, Moussa MAA. Survival and predictors of death among primary  
459 immunodeficient patients: a registry-based study. *J Clin Immunol.* 2012  
460 Jun;32(3):467–73.
- 461 39. Lion T. Adenovirus infections in immunocompetent and immunocompromised  
462 patients. *Clin Microbiol Rev.* 2014 Jul;27(3):441–62.
- 463 40. Sun C, Zhang Y, Feng L, Pan W, Zhang M, Hong Z, et al. Epidemiology of  
464 adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in  
465 Guangzhou, southern China. *Vaccine.* 2011 May 17;29(22):3837–41.
- 466 41. De Jong PieterJ, Spigland I, Valderrama G, Horwitz MarshallS. Adenovirus Isolates  
467 from Urine of Patients with Acquired Immunodeficiency Syndrome. *The Lancet.*  
468 1983 Jun 11;321(8337):1293–6.
- 469 42. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, et al.  
470 Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a  
471 vaccine vector. *AIDS.* 2004 May 21;18(8):1213–6.

- 472 43. Zhang S, Huang W, Zhou X, Zhao Q, Wang Q, Jia B. Seroprevalence of neutralizing  
473 antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus  
474 type-68 in healthy Chinese adults. *J Med Virol*. 2013 Jun;85(6):1077–84.
- 475 44. Yu B, Dong J, Wang C, Zhan Y, Zhang H, Wu J, et al. Characteristics of neutralizing  
476 antibodies to adenovirus capsid proteins in human and animal sera. *Virology*.  
477 2013;437(2):118–23.
- 478 45. Kremer EJ. What is the risk of a deadly adenovirus pandemic? *PLoS Pathog*. 2021  
479 Sep;17(9):e1009814.
- 480 46. Russell KL, Broderick MP, Franklin SE, Blyn LB, Freed NE, Moradi E, et al.  
481 Transmission dynamics and prospective environmental sampling of adenovirus in a  
482 military recruit setting. *J Infect Dis*. 2006 Oct 1;194(7):877–85.
- 483 47. Zimmermann P, Curtis N. Factors That Influence the Immune Response to  
484 Vaccination. *Clinical Microbiology Reviews* [Internet]. 2019;32(2). Available from:  
485 <https://cmr.asm.org/content/32/2/e00084-18>
- 486 48. Chéneau C, Kremer EJ. Adenovirus-Extracellular Protein Interactions and Their  
487 Impact on Innate Immune Responses by Human Mononuclear Phagocytes. *Viruses*.  
488 2020 Nov 26;12(12).
- 489 49. Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L. Use of adenovirus type-5  
490 vectored vaccines: a cautionary tale. *Lancet*. 2020 Oct 31;396(10260):e68–9.
- 491 50. Logunov DY, Livermore DM, Ornelles DA, Bayer W, Marques E, Czerkinsky C, et  
492 al. COVID-19 vaccination and HIV-1 acquisition. *The Lancet*. 2022  
493 Apr;399(10333):e34–5.

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad

494 **Table**


<b>Regional Sample</b>	<b>Overall</b>	<b>Burkina Faso Bobo-dioulasso /Ouagadougou</b>	<b>Chad N'Djamena</b>	<b>France Montpellier</b>
<b>Number of Sample (%)</b>	424 (100)	281 (66,3)	93 (21,9)	50 (11,8)
<b>Sex, n (%), %)</b>				
<b>Male</b>	154 (36,3)	107 (30,1)	35 (37,6)	12 (36)
<b>Female</b>	252 (59,5)	174 (69,9)	58 (62,4)	20 (26)
<b>unknown</b>	18 (4,2)	0	0	18 (38)
<b>Age range, Mean Age</b>	7 months - 82 years 28,6 years	10 months - 82 years 27,9 years	7 months - 59 years 30,2 years	20 - 55 years 29,5 years
<b>Age, year; n (%)</b>				
<b>(0-9)</b>	48	37 (13,2)	11 (11,8)	0
<b>(10-17)</b>	51	49 (17,4)	2 (2,2)	0
<b>(18-25)</b>	100	62 (22,1)	21 (22,6)	17 (34)
<b>(26-44)</b>	131	78 (27,7)	43 (46,2)	10 (20)
<b>(≥45)</b>	75	55 (19,6)	15 (16,1)	5 (10)
<b>Unknown</b>	19	0	1 (1,1)	18 (36)
<b>HIV status, n (%)</b>				
<b>Negative</b>	358 (84,4)	261 (92,8)	47 (50,5)	50 (100)
<b>Positive</b>	66 (15,6)	20 (7,2)	46 (49,5)	0 (0)

495

496 **Table 01: Demographics data**




497 **Figures**




498  
499 **Figure 1:** HAdV-C5, HAdV-D26, and HAdV-B35 NAb seroprevalence (bars: mean ± SEM) in  
500 healthy individuals from Burkina Faso, Chad and France. Statistical analyses were performed  
501 by Kruskal Wallis non-parametric Anova statistical test. p values are denoted as: ns: not  
502 significant, \*p < 0.05; \*\* p < 0.01; \*\*\* p < 0.001 and \*\*\*\* p < 0.0001.

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad



503

504 **Figure 2:** Distribution of HAdV-C5 and HAdV-D26 NAb titers in healthy individuals from  
 505 Burkina Faso, Chad and France. **(A)** NAb titers were arbitrarily stratified into the following  
 506 categories:  $\leq 99$ , 100-999 and  $\geq 1000$ . **(B)** Percentage of positive samples (NAb titer  $\geq 100$ ).  
 507 **(C)** Distribution (percentage) of NAb titers among positive samples from Burkina Faso. NAb  
 508 titer was divided into three groups: low (100-499), medium (500-999) and high ( $\geq 1000$ ).



509

510 **Figure 3:** TNF secretion was used as a surrogate for MoDC activation following *in vitro*

511 activation by various plasma from healthy individuals from Burkina Faso, pre-incubated with

512 HAdV-C5, HAdV-D26 or HAdV-B35. (A) Individual and average (mean  $\pm$  SEM) TNF

513 secretion according to plasma serology profiles. Samples were classified into four groups:

514 (C5+ D26+); (C5- D26-); (C5- D26+); (C5+ D26+) and individually pre-incubated with

515 HAdV-C5 (●) or HAdV-D26 (■). Positive samples (NAb titer  $\geq$  100). (B) Correlation

516 between plasma NAb titers and TNF secretion by MoDC. (C) Mean (with SEM) TNF secretion


517 by MoDC in presence of plasma individually pre-incubated with HAdV-C5, HAdV-D26 or

518 HAdV-B35. Comparisons were performed by Kruskal Wallis non-parametric ANOVA

519 statistical test. Correlation were performed with the non-parametric Spearman test.  $r$ , (rho) =


520 Spearman rank correlation.  $p$  values are denoted as: \* $p < 0.05$ ; \*\*  $p < 0.01$ ; and \*\*\*  $p < 0.001$ .

Ouoba/Paris et al., HAdVs seroprevalence in Burkina Faso and Chad



521  
 522 **Figure 4:** Overall HAdV-C5, HAdV-D26 and HAdV-B35 NAb titers and TNF secretion by  
 523 MoDC challenged with plasma from HIV-infected (HIV+) individuals or uninfected controls  
 524 (HIV-) from Burkina Faso or Chad, pre-incubated with various HAdVs. **(A)** Mean (with SEM)  
 525 NAb titers among HIV-infected and HIV-uninfected populations. **(B)** Percentage of positive  
 526 samples among HIV-infected subjects in Chad (NAb titer  $\geq$  100). **(C)** Correlation between  
 527 plasma NAb titers and TNF secretion and **(D)** mean (with SEM) TNF secretion by MoDC  
 528 challenged with plasma from healthy or HIV+ groups from Chad, pre-incubated with HAdV-  
 529 C5, HAdV-D26 or HAdV-35. Statistical analysis were made using Mann Whitney or Kruskal  
 530 Wallis ANOVA non-parametric tests for comparisons between two or multiples groups,  
 531 respectively. Correlations were made with the non-parametric Spearman test.  $r_s$  (rho) =  
 532 Spearman rank correlation. p values are denoted as: ns: not significant, \*p < 0.05; \*\* p < 0.01;  
 533 \*\*\* p < 0.001 and \*\*\*\* p < 0.0001.

534 **Supplementary data**



535

536 **Figure S1:** Overall HAdV-C5 and HAdV-D26 NAb titers among healthy individuals from

537 Burkina Faso according to (A) single- or dual-positive groups (box-plots shows the minimum,

538 first quartile, median, third quartile and maximum titer levels) and (B) gender groups (mean


539 with SEM). (C) Distribution of NAb titers among males (n = 107) and females (n = 154)

540 groups. NAb titers was stratified into 4 groups: negative (0-99), low (100-499), medium (500-

541 999) and high ( $\geq 1000$ ). Comparison was performed using the non-parametric Mann Whitney

542 statistical test. ns: not significant, \* $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

543



544

545 **Figure S2:** NAb seroprevalence against HAdV-C5 and HAdV-D26 among different age groups  
546 of healthy individuals from Burkina Faso. (A) Percentage of positive samples (NAb titer  $\geq$   
547 100) among different age groups for HAdV-C5 (Black bar) and HAdV-D26 (grey bar). (B)  
548 Mean NAb seroprevalence (mean  $\pm$  range) among different age groups of healthy positive  
549 subjects from Burkina Faso. Comparisons were performed by Kruskal Wallis non-parametric  
550 ANOVA statistical test.